Wounds - Pipeline Review, H2 2016

Date: December 30, 2016
Pages: 224
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until March 3, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W00F0C8433BEN
Leaflet:

Download PDF Leaflet

Wounds - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds – Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 56, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Wounds Overview
Therapeutics Development
Pipeline Products for Wounds - Overview
Pipeline Products for Wounds - Comparative Analysis
Wounds - Therapeutics under Development by Companies
Wounds - Therapeutics under Investigation by Universities/Institutes
Wounds - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Wounds - Products under Development by Companies
Wounds - Products under Investigation by Universities/Institutes
Wounds - Companies Involved in Therapeutics Development
Aerpio Therapeutics Inc
AlgiPharma AS
AmpliPhi Biosciences Corp
AndroScience Corp
Aridis Pharmaceuticals LLC
Beech Tree Labs Inc
Bio3 Research Srl
Biotec Pharmacon ASA
Blueberry Therapeutics Ltd
Cellphire Inc
CorMedix Inc
Dermala Inc
Destiny Pharma Ltd
Escape Therapeutics Inc
EyeGene Inc
FibroGen Inc
GangaGen Inc
Gene Signal International SA
GlaxoSmithKline Plc
IC-MedTech Inc
Living Cell Technologies Ltd
Madam Therapeutics BV
miRagen Therapeutics Inc
NatureWise Biotech & Medicals Corp
Novan Inc
NuvOx Pharma LLC
Octapharma AG
Omeros Corp
Osiris Therapeutics Inc
Pacific Northwest Biotechnology LLC
Pharmaxis Ltd
ProMetic Life Sciences Inc
RiverTown Therapeutics Inc
RMB-Research GmbH
RXi Pharmaceuticals Corp
Sinclair Pharma Plc
SomaGenics Inc
Stratatech Corp
TGV-Laboratories
Thesan Pharmaceuticals Inc
Topadur Pharma AG
Trophogen Inc
Tumorend LLC
VBS Pharmaceuticals
viDA Therapeutics Inc
Wounds - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
A-3APO - Drug Profile
ABSA-01 - Drug Profile
AKB-4924 - Drug Profile
ALLO-ASC - Drug Profile
AlloGraf - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile
APO-1 - Drug Profile
APO-2 - Drug Profile
AR-101 - Drug Profile
Arginine Butyrate - Drug Profile
ARN-077 - Drug Profile
ASCJ-9 - Drug Profile
B-244 - Drug Profile
BB-1000 - Drug Profile
BDM-I - Drug Profile
BTL-slo - Drug Profile
CAR Peptide - Drug Profile
Cell Therapy for Chronic Wounds - Drug Profile
Cell Therapy for Dermatology and Immunology - Drug Profile
Cell Therapy for Wounds - Drug Profile
CM-101 - Drug Profile
CRMD-004 - Drug Profile
CTR-2 - Drug Profile
daprodustat - Drug Profile
DB-2121 - Drug Profile
Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile
Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile
Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
EGS-001 - Drug Profile
FG-6874 - Drug Profile
G-3KL - Drug Profile
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
Gene Therapy to Activate HSP60 for Wounds - Drug Profile
GS-156 - Drug Profile
Human Growth Factor - Drug Profile
hVGF - Drug Profile
JM-2 - Drug Profile
KL-7016 - Drug Profile
LWnt-3a - Drug Profile
MG-53 - Drug Profile
MMP-26051 - Drug Profile
MMP-26052 - Drug Profile
molgramostim - Drug Profile
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
MRG-110 - Drug Profile
Mul-1867 - Drug Profile
NBM-67 - Drug Profile
ND-336 - Drug Profile
NTCELL - Drug Profile
Oligomer G for Wounds And Burns - Drug Profile
OTI-1011 - Drug Profile
OTI-1502 - Drug Profile
P-128 - Drug Profile
P-148 - Drug Profile
Panaecin - Drug Profile
perflenapent for wound healing - Drug Profile
Perlecan - Drug Profile
PGF - Drug Profile
plasminogen (recombinant) - Drug Profile
Polysaccharide for Wounds and Scars - Drug Profile
Protein for Diabetic Wound Healing - Drug Profile
Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile
Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile
Protein to Activate FGF2 for Wound Healing - Drug Profile
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
PXS-4820 - Drug Profile
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile
Recombinant Protein to Inhibit SEB and TSST-1 for Pulmonary Infections, Bacterial Infections, Toxic Shock and Wounds - Drug Profile
Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
RT-1740 - Drug Profile
SG-404 - Drug Profile
silver sulfadiazine - Drug Profile
Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile
Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile
Small Molecule to Target LGR6 for Dermatology - Drug Profile
Small Molecules for Staphylococcal Infections and Wounds - Drug Profile
Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
Soluble Beta Glucan - Drug Profile
Statmicoll - Drug Profile
Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile
Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Thrombosomes - Drug Profile
Tolecine - Drug Profile
TOPN-53 - Drug Profile
TRBN-0224 - Drug Profile
TWB-103 - Drug Profile
V-2248 - Drug Profile
VTI-3000 Series - Drug Profile
WH-1 - Drug Profile
XF-70 - Drug Profile
Wounds - Dormant Projects
Wounds - Discontinued Products
Wounds - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Wounds, H2 2016
Number of Products under Development for Wounds - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Wounds - Pipeline by Aerpio Therapeutics Inc, H2 2016
Wounds - Pipeline by AlgiPharma AS, H2 2016
Wounds - Pipeline by AmpliPhi Biosciences Corp, H2 2016
Wounds - Pipeline by AndroScience Corp, H2 2016
Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Wounds - Pipeline by Beech Tree Labs Inc, H2 2016
Wounds - Pipeline by Bio3 Research Srl, H2 2016
Wounds - Pipeline by Biotec Pharmacon ASA, H2 2016
Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2016
Wounds - Pipeline by Cellphire Inc, H2 2016
Wounds - Pipeline by CorMedix Inc, H2 2016
Wounds - Pipeline by Dermala Inc, H2 2016
Wounds - Pipeline by Destiny Pharma Ltd, H2 2016
Wounds - Pipeline by Escape Therapeutics Inc, H2 2016
Wounds - Pipeline by EyeGene Inc, H2 2016
Wounds - Pipeline by FibroGen Inc, H2 2016
Wounds - Pipeline by GangaGen Inc, H2 2016
Wounds - Pipeline by Gene Signal International SA, H2 2016
Wounds - Pipeline by GlaxoSmithKline Plc, H2 2016
Wounds - Pipeline by IC-MedTech Inc, H2 2016
Wounds - Pipeline by Living Cell Technologies Ltd, H2 2016
Wounds - Pipeline by Madam Therapeutics BV, H2 2016
Wounds - Pipeline by miRagen Therapeutics Inc, H2 2016
Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016
Wounds - Pipeline by Novan Inc, H2 2016
Wounds - Pipeline by NuvOx Pharma LLC, H2 2016
Wounds - Pipeline by Octapharma AG, H2 2016
Wounds - Pipeline by Omeros Corp, H2 2016
Wounds - Pipeline by Osiris Therapeutics Inc, H2 2016
Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H2 2016
Wounds - Pipeline by Pharmaxis Ltd, H2 2016
Wounds - Pipeline by ProMetic Life Sciences Inc, H2 2016
Wounds - Pipeline by RiverTown Therapeutics Inc, H2 2016
Wounds - Pipeline by RMB-Research GmbH, H2 2016
Wounds - Pipeline by RXi Pharmaceuticals Corp, H2 2016
Wounds - Pipeline by Sinclair Pharma Plc, H2 2016
Wounds - Pipeline by SomaGenics Inc, H2 2016
Wounds - Pipeline by Stratatech Corp, H2 2016
Wounds - Pipeline by TGV-Laboratories, H2 2016
Wounds - Pipeline by Thesan Pharmaceuticals Inc, H2 2016
Wounds - Pipeline by Topadur Pharma AG, H2 2016
Wounds - Pipeline by Trophogen Inc, H2 2016
Wounds - Pipeline by Tumorend LLC, H2 2016
Wounds - Pipeline by VBS Pharmaceuticals, H2 2016
Wounds - Pipeline by viDA Therapeutics Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Wounds - Dormant Projects, H2 2016
Wounds - Dormant Projects (Contd..1), H2 2016
Wounds - Dormant Projects (Contd..2), H2 2016
Wounds - Dormant Projects (Contd..3), H2 2016
Wounds - Dormant Projects (Contd..4), H2 2016
Wounds - Dormant Projects (Contd..5), H2 2016
Wounds - Dormant Projects (Contd..6), H2 2016
Wounds - Dormant Projects (Contd..7), H2 2016
Wounds - Dormant Projects (Contd..8), H2 2016
Wounds - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Wounds, H2 2016
Number of Products under Development for Wounds - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Fracture - Pipeline Review, H2 2014 US$ 1,500.00 Aug, 2014 · 73 pages

Ask Your Question

Wounds - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: